Drug Profile

HIV-1 vaccine - Sumagen

Alternative Names: Killed-whole HIV-1 vaccine; SAV-001; SAV-001H

Latest Information Update: 31 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Western Ontario
Developer Sumagen
Class AIDS vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - HIV infections

Highest Development Phases

Phase I HIV-1 infections

Most Recent Events

29 Oct 2024 HIV-1 vaccine is still in phase-I development in HIV-1-infections in USA (IM, Injection)
29 Oct 2024 Sumagen plans a phase I/II trial for HIV-1 infections in by the end of 2025
28 Jul 2018 No recent reports of development identified for phase-I development in HIV-1-infections in USA (IM, Injection)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com